Oncolytic Viral Therapy for Glioma by Recombinant Sindbis Virus.

ABSTRACT:

Background

The characteristics of glioblastoma, such as drug resistance during treatment, short patient survival, and high recurrence rates, have made patients with glioblastoma more likely to benefit from oncolytic therapy.

Methods

In this study, we investigated the safety of the sindbis virus by injecting virus intravenously and intracranially in mice and evaluated the therapeutic effect of the virus carrying different combinations of IL-12, IL-7, and GM-CSF on glioma in a glioma-bearing mouse model.

Results

SINV was autologously eliminated from the serum and organs as well as from neural networks after entering mice. Furthermore, SINV was restricted to the injection site in the tree shrew brain and did not spread throughout the whole brain. In addition, we found th

SUBMITTER: Sun K 

PROVIDER: S-EPMC10571546 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature